Analysis

Lexeo Therapeutics, Inc. (LXEO) Stock Analysis

Lexeo Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to LXEO.

websiteLXEO/analysis/LXEO

Lexeo Therapeutics, Inc.

Lexeo Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to LXEO.

Stock profile

Ticker

LXEO

Asset type

Stock

Market cap

$387.1M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Lexeo Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • LXEO primary listing

Latest Lexeo Therapeutics, Inc. news

Lexeo Therapeutics Announces Publication in JAMA Cardiology of Phase I/II Data for LX2006 in Friedreich Ataxia

Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies SUNRISE-FA 2 pivotal study for LX2006 on tr...

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics Announces Regulatory Update and Registrational Trial Design for LX2006 Gene Therapy in Friedreich Ataxia

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Lexeo Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference

Lexeo Therapeutics Reports First Quarter 2026 Financial Results and Operational Highlights

SUNRISE-FA 2 open-label, pivotal trial protocol and SAP for LX2006 submitted to FDA in Q1 2026; Awaiting final FDA feedback Multiple presentations highlighting progress across c...

Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

Oral and poster presentations highlight progress across cardiac genetic medicine pipeline and optimized, Sf9-baculovirus AAV manufacturing platformNEW YORK, April 27, 2026 (GLOB...

Research sections

Valuation

Review valuation context for Lexeo Therapeutics, Inc..

Future growth

Review future growth context for Lexeo Therapeutics, Inc..

Past performance

Review past performance context for Lexeo Therapeutics, Inc..

Financial health

Review financial health context for Lexeo Therapeutics, Inc..

Dividend

Review dividend context for Lexeo Therapeutics, Inc..

Management

Review management context for Lexeo Therapeutics, Inc..

Ownership

Review ownership context for Lexeo Therapeutics, Inc..

Other information

Review other information context for Lexeo Therapeutics, Inc..

Community

Review community context for Lexeo Therapeutics, Inc..